Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (QTRX) is a leader in ultra-sensitive digital immunoassay technology, enabling groundbreaking advancements in precision diagnostics and life sciences research. This dedicated news hub provides investors and industry professionals with comprehensive updates on the company's scientific developments and strategic initiatives.
Access timely, verified information about Quanterix's product innovations, research collaborations, and financial performance. Our curated collection includes earnings announcements, technology milestones, regulatory updates, and strategic partnerships that demonstrate the company's impact on biomarker detection capabilities.
Stay informed about QTRX's progress in commercializing its Simoa platform and expanding applications in neurological disorders, oncology, and infectious disease research. All content is meticulously organized to help stakeholders track the company's role in advancing next-generation diagnostic solutions.
Bookmark this page for direct access to official Quanterix communications and third-party analyses. Regularly updated with material developments, this resource supports informed decision-making about one of healthcare's most innovative diagnostic technology providers.
Quanterix (NASDAQ: QTRX), a company specializing in ultrasensitive biomarker detection, has announced its plans to report second quarter 2024 financial results. The company will host a conference call on Thursday, August 8, 2024, at 4:30 p.m. E.T. to discuss these results. Prior to the call, Quanterix will issue a press release detailing the Q2 2024 earnings after the market closes on the same day.
Investors can access the live webcast from the News & Events page within the Investors section of the Quanterix website. For those interested in participating, pre-registration links are available for both webcast and audio-only options. An archived webcast replay will be accessible on the company's website for one year following the call.
Quanterix (NASDAQ: QTRX) presented new data at the Alzheimer's Association International Conference (AAIC) demonstrating a novel multi-marker approach for Alzheimer's disease (AD) detection. This approach significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test while maintaining high accuracy above 90%. The multi-marker method combines p-Tau 217 with other AD-associated plasma biomarkers, including amyloid β 42, amyloid β 40, GFAP, and NfL, in an algorithm that provides a single risk score.
Key findings include:
- Reduced intermediate zone from 31.2% to 10.5% compared to p-Tau 217 alone
- Accurate amyloid classifications for 151 of 228 previously uncertain results
- Potential to provide diagnostic certainty for more patients
Quanterix plans to launch a multi-marker laboratory developed test later this year through its LucentAD product line.
Quanterix (NASDAQ: QTRX) has announced that its CEO, Masoud Toloue, and CFO, Vandana Sriram, will participate in the Scotiabank Healthcare 1x1 Day on June 20, 2024. Known for its ultrasensitive biomarker detection technology, Quanterix aims to showcase its advancements and strategies. For more details, visit their official website and explore their Simoa® technology.
Quanterix (NASDAQ: QTRX) announced the participation of its CEO Masoud Toloue and CFO Vandana Sriram at the 45th Annual Goldman Sachs Global Healthcare Conference. The company specializes in ultrasensitive biomarker detection to advance scientific discovery. The fireside chat presentation is scheduled for June 12, 2024, at 2:40 p.m. EST and will be webcast live. Replays will be available for a time post-conference. For more details, visit the Investor Relations section on Quanterix's website.
Quanterix (NASDAQ: QTRX), a leader in biomarker detection technology, announced that its CEO, Masoud Toloue, will participate in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for May 29, 2024, at 11:40 a.m. ET and will be available via a live webcast.
Replays will be accessible for a time post-conference. For more details, visit Quanterix’s official website.
Quanterix , a biomarker detection company, reported financial results for Q1 2024 with revenue of $32.1 million, a 12.7% increase year-over-year. The company is focused on developing new assays to detect neuro-pathologies like Alzheimer's, Parkinson's, and Multiple Sclerosis. Key highlights include the launch of a blood test for Alzheimer's and maintaining a strong cash position. The company reaffirmed its 2024 financial guidance with revenue expected in the range of $139 to $144 million.
Quanterix (NASDAQ: QTRX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results. The press release will be issued on May 7, 2024, after the market closes. Interested investors can access the webcast and dial-in information on the Quanterix website.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
